Featured Research

from universities, journals, and other organizations

Relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria

Date:
January 22, 2010
Source:
Public Library of Science
Summary:
New research synthesizes information from many different studies that attempt to link specific antibody responses to Plasmodium falciparum with protection from clinical malaria and comes to important conclusions about which antigens might be worth advancing as vaccine candidates.

Research published this week in PLoS Medicine synthesizes information from many different studies that attempt to link specific antibody responses to Plasmodium falciparum with protection from clinical malaria and comes to important conclusions about which antigens might be worth advancing as vaccine candidates.

Related Articles


Malaria is a major global health problem. P. falciparum is the major cause and kills about one million people every year, mainly young children. However, immune responses to malaria are poorly understood, which has hindered the development of a vaccine against malaria. Antibody responses to proteins (antigens) produced by the merozoite life stage of malaria might protect against subsequent malaria infection. Therefore studying these antibody responses could be useful for identifying antigens to incorporate into vaccines against malaria.

Numerous studies have been performed on human antibody responses to P. falciparum merozoite antigens, but they have given conflicting results. Freya Fowkes and colleagues have completed a systematic review with meta-analysis for the first time of immune responses to P. falciparum. This study confirms that merozoite antigens are important targets of protective immunity in people and identifies specific antigens that could be prioritized for vaccine development. Specifically, in people with antibodies to the merozoite proteins MSP-3 and MSP-119, the risk of developing P. falciparum malaria was reduced by 54% and 18%, respectively, compared to people without antibodies to these antigens. Antibodies to other antigens, such as AMA1 were also linked with substantial protection from malaria.

The authors recommend that new prospective cohort studies are urgently needed to guide vaccine development. These studies must include a larger number of lead antigens and populations outside Africa.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis. PLoS Med, 2010; 7(1): e1000218 DOI: 10.1371/journal.pmed.1000218

Cite This Page:

Public Library of Science. "Relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria." ScienceDaily. ScienceDaily, 22 January 2010. <www.sciencedaily.com/releases/2010/01/100119133504.htm>.
Public Library of Science. (2010, January 22). Relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/01/100119133504.htm
Public Library of Science. "Relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria." ScienceDaily. www.sciencedaily.com/releases/2010/01/100119133504.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins